Laura M. Spring

6.7k total citations · 3 hit papers
132 papers, 3.4k citations indexed

About

Laura M. Spring is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Laura M. Spring has authored 132 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 60 papers in Cancer Research. Recurrent topics in Laura M. Spring's work include Advanced Breast Cancer Therapies (50 papers), HER2/EGFR in Cancer Research (40 papers) and Breast Cancer Treatment Studies (39 papers). Laura M. Spring is often cited by papers focused on Advanced Breast Cancer Therapies (50 papers), HER2/EGFR in Cancer Research (40 papers) and Breast Cancer Treatment Studies (39 papers). Laura M. Spring collaborates with scholars based in United States, United Kingdom and Italy. Laura M. Spring's co-authors include Aditya Bardia, Beverly Moy, Seth A. Wander, Steven J. Isakoff, Leif W. Ellisen, Fabrice André, Mark L. Zangardi, Nicholas C. Turner, Jamie O. Brett and Michele A. Gadd and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Laura M. Spring

123 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

2018 414 citations Ioanna Keklikoglou, Chiara Cianciaruso et al. Nature Cell Biology profile →
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

2020 312 citations Laura M. Spring, Seth A. Wander et al. profile →
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

2021 185 citations Laura M. Spring, Aditya Bardia et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura M. Spring United States	27	2.2k	1.3k	1.2k	835	402	132	3.4k
Luís Manso Spain	22	1.9k 0.9×	1.6k 1.2×	802 0.7×	710 0.9×	221 0.5×	153	3.3k
Toshinari Yamashita Japan	24	1.9k 0.9×	1.6k 1.2×	1.1k 0.9×	1.3k 1.6×	211 0.5×	135	3.7k
Erica L. Mayer United States	31	2.6k 1.2×	997 0.7×	1.2k 1.0×	1.4k 1.7×	297 0.7×	144	4.7k
Stephen D. Rubin United States	13	2.6k 1.2×	1.3k 1.0×	673 0.6×	1.1k 1.3×	811 2.0×	17	4.0k
Maria Schwaederlé United States	28	1.5k 0.7×	1.1k 0.8×	1.7k 1.4×	1.0k 1.2×	243 0.6×	43	3.2k
Chikako Shimizu Japan	30	2.1k 1.0×	837 0.6×	689 0.6×	1.0k 1.2×	707 1.8×	180	3.7k
Philippe Aftimos Belgium	25	1.9k 0.9×	809 0.6×	785 0.6×	934 1.1×	690 1.7×	144	3.1k
Andrea Rocca Italy	33	2.3k 1.0×	911 0.7×	1.3k 1.0×	1.1k 1.3×	413 1.0×	135	4.1k
Cristina Saura Spain	35	3.0k 1.4×	1.5k 1.2×	1.2k 1.0×	1.3k 1.5×	877 2.2×	201	4.4k
Leticia De Mattos‐Arruda Spain	26	1.3k 0.6×	735 0.5×	1.4k 1.2×	947 1.1×	215 0.5×	54	2.7k

Countries citing papers authored by Laura M. Spring

Since Specialization

Citations

This map shows the geographic impact of Laura M. Spring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. Spring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. Spring more than expected).

Fields of papers citing papers by Laura M. Spring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura M. Spring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. Spring. The network helps show where Laura M. Spring may publish in the future.

Co-authorship network of co-authors of Laura M. Spring

This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. Spring. A scholar is included among the top collaborators of Laura M. Spring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. Spring. Laura M. Spring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sood, Rupali, Andrzej Niemierko, Laura M. Spring, et al.. (2025). Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer. Clinical Cancer Research. 31(7). 1315–1322. 1 indexed citations

Abdou, Yara, Prarthna V Bhardwaj, Rachel O. Abelman, et al.. (2024). Abstract PO3-05-14: Practice patterns for sequential use of antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer: results from a physician survey. Cancer Research. 84(9_Supplement). PO3–5. 1 indexed citations

Medford, Arielle J., Andrzej Niemierko, Rachel O. Abelman, et al.. (2024). Nectin-4 expression in primary breast cancer and associated clinical outcomes.. Journal of Clinical Oncology. 42(16_suppl). 570–570.

Metzger, Otto, Nabihah Tayob, Giuseppe Viale, et al.. (2024). Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer. Cancer Research. 84(9_Supplement). PS09–2. 2 indexed citations

Abelman, Rachel O., Bogang Wu, Laura M. Spring, Leif W. Ellisen, & Aditya Bardia. (2023). Mechanisms of Resistance to Antibody–Drug Conjugates. Cancers. 15(4). 1278–1278. 76 indexed citations

Medford, Arielle J., Lauren Oshry, Bariş Boyraz, et al.. (2023). TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic Advances in Medical Oncology. 15. 2597580–2597580. 5 indexed citations

Medford, Arielle J., Beverly Moy, Laura M. Spring, et al.. (2023). Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical Cancer Research. 29(22). 4540–4548. 25 indexed citations

Spring, Laura M., William E. Barlow, Aditya Bardia, et al.. (2023). Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER). Cancer Research. 83(5_Supplement). HER2–19. 1 indexed citations

Medford, Arielle J., Ignaty Leshchiner, Lesli A. Kiedrowski, et al.. (2023). ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1074–1074. 1 indexed citations

10.

Rojas, Kristin E., et al.. (2023). Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects. Annals of Surgical Oncology. 30(10). 5951–5961. 3 indexed citations

11.

Spring, Laura M., Yael Bar, & Steven J. Isakoff. (2022). The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. Journal of the National Comprehensive Cancer Network. 20(6). 723–734. 37 indexed citations

12.

Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413. 12 indexed citations

13.

Griffiths, Jason I., Jinfeng Chen, Patrick A. Cosgrove, et al.. (2021). Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer. 2(6). 658–671. 41 indexed citations

14.

Medford, Arielle J., Laura M. Spring, Beverly Moy, & Aditya Bardia. (2021). Antibody drug conjugates for patients with breast cancer. Current Problems in Cancer. 45(5). 100795–100795. 3 indexed citations

15.

Metzger, Otto, Giuseppe Viale, Shayna Stein, et al.. (2021). Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery. 11(10). 2474–2487. 148 indexed citations

16.

Smith, Barbara L., Bridget N. Kelly, Michelle C. Specht, et al.. (2020). A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Research and Treatment. 183(3). 515–524. 13 indexed citations

17.

Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262. 15 indexed citations

18.

Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451. 47 indexed citations

19.

Kwan, Tanya T., Aditya Bardia, Laura M. Spring, et al.. (2018). A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discovery. 8(10). 1286–1299. 78 indexed citations

20.

Keklikoglou, Ioanna, Chiara Cianciaruso, Esra Güç, et al.. (2018). Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology. 21(2). 190–202. 414 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact